肿瘤相关抗原特异性T细胞联合纳武利尤单抗治疗复发难治性霍奇金淋巴瘤安全且持续存在
该研究评估靶向WT1、PRAME和Survivin的肿瘤相关抗原特异性T细胞(TAA-Ts)单独或联合纳武利尤单抗治疗复发/难治性霍奇金淋巴瘤的安全性和疗效,10例患者输注TAA-Ts后安全,无明确剂量限制性毒性,辅助治疗患者持续缓解3年以上,活动性疾病患者中1例完全缓解、7例稳定。
要点
- TAA-Ts输注安全,无明确剂量限制性毒性。
- 辅助治疗患者持续缓解超过3年。
- 活动性疾病患者中1例完全缓解、7例稳定,3例稳定超过1年。
核心结论
- TAA-Ts单独或联合纳武利尤单抗治疗复发/难治性霍奇金淋巴瘤安全并产生有前景的结果。
研究设计与样本
- 10例复发/难治性霍奇金淋巴瘤患者输注TAA-Ts(8例自体、2例异体),其中8例活动性疾病、2例造血干细胞移植后辅助治疗;6例接受纳武利尤单抗预处理。
主要发现
- 所有10例产品识别1种以上TAA且为多功能的。
- 辅助治疗患者持续缓解3年以上。
- 8例活动性疾病患者中1例完全缓解、7例3个月时稳定,其中3例1年时仍稳定。
- 应答患者中观察到抗原扩展和TAA-Ts长期体内持续存在。
- 纳武利尤单抗预处理影响TAA-T识别和持续存在。
临床怎么用
- TAA-Ts单独或联合纳武利尤单抗可作为复发/难治性霍奇金淋巴瘤的安全治疗选择。
局限性
- 样本量小(10例),需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hodgkin lymphoma (HL) Reed Sternberg cells express tumor-associated antigens (TAA) that are potential targets for cellular therapies. We recently demonstrated that TAA-specific T cells (TAA-Ts) targeting WT1, PRAME, and Survivin were safe and associated with prolonged time to progression in solid tumors. Hence, we evaluated whether TAA-Ts when given alone or with nivolumab were safe and could elicit antitumor effects in vivo in patients with relapsed/refractory (r/r) HL. Ten patients were infused with TAA-Ts (8 autologous and 2 allogeneic) for active HL (n = 8) or as adjuvant therapy after hematopoietic stem cell transplant (n = 2). Six patients received nivolumab priming before TAA-Ts and continued until disease progression or unacceptable toxicity. All 10 products recognized 1 or more TAAs and were polyfunctional. Patients were monitored for safety for 6 weeks after the TAA-Ts and for response until disease progression. The infusions were safe with no clear dose-limiting toxicities. Patients receiving TAA-Ts as adjuvant therapy remain in continued remission at 3+ years. Of the 8 patients with active disease, 1 patient had a complete response and 7 had stable disease at 3 months, 3 of whom remain with stable disease at 1 year. Antigen spreading and long-term persistence of TAA-Ts in vivo were observed in responding patients. Nivolumab priming impacted TAA-T recognition and persistence. In conclusion, treatment of patients with r/r HL with TAA-Ts alone or in combination with nivolumab was safe and produced promising results. This trial was registered at www.clinicaltrials.gov as #NCT022039303 and #NCT03843294.
引用
- Dave H, Terpilowski M, Mai M, et al. Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma. Blood Adv. 2022. PMID: 34495306. doi:10.1182/bloodadvances.2021005343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。